NASD · Healthcare · Biotechnology · USA
Beam Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Beam Therapeutics is a biotechnology company developing precision genetic medicines based on its proprietary base editing technology, which modifies individual DNA bases without creating double-stranded breaks. The company advances a portfolio of investigational therapies targeting hematology and genetic diseases through ex vivo and in vivo delivery approaches, supported by internal manufacturing capabilities at its facility in North Carolina.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Beam Therapeutics Inc stock.
Overvalued: intrinsic value $11.10 per share, market price $20.65, margin of safety -86.1% (as of 2026-11-17).
A 2.4x revenue multiple, discounted for its losses, values the shares at $11.10; the price of $20.65 is 86% above that value.
17 more funds hold it; the full list is part of the paid plan.
49 more in this industry show a wider margin of safety.
BEAM is overvalued (as of the 2026-11-17 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $11.10; the price of $20.65 is 86% above that value.
$11.10 per share (as of the 2026-11-17 close), against a market price of $20.65. That is a margin of safety of -86.1%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.